Literature DB >> 11953734

Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.

Douglas J Scothorn1, Cynthia Price, Daniel Schwartz, Cindy Terrill, George R Buchanan, Wanda Shurney, Ingrid Sarniak, Robert Fallon, Jen-Yih Chu, Charles H Pegelow, Winfred Wang, James F Casella, Linda S Resar, Brian Berman, Thomas Adamkiewicz, Lewis L Hsu, Kwaku Ohene-Frempong, Kim Smith-Whitley, Donald Mahoney, J Paul Scott, Gerald M Woods, Masayo Watanabe, Michael R Debaun.   

Abstract

OBJECTIVE: To test the hypothesis that children with sickle cell disease (SCD) who have an initial stroke temporally unrelated to another medical event are at higher risk for recurrent stroke than are children who had strokes temporally related to medical events.
METHODS: A retrospective cohort study of children with SCD and stroke who received regularly scheduled blood transfusions for a minimum of 5 years was conducted. Medical records were examined for the documentation of antecedent or concurrent medical events (hypertension, acute chest syndrome, aplastic crisis, fever associated with infection, exchange transfusion) associated with physician contact within 14 days before the initial stroke.
RESULTS: A total of 137 pediatric patients from 14 centers were studied. Mean age at first stroke was 6.3 years (1.4 to 14.0 years) with mean follow-up of 10.1 years (5 to 24 years). Thirty-one (22%) patients had a second stroke (2.2 per 100 patient years); 26 patients had an identified medical or concurrent event associated with their initial stroke. None of these patients had recurrent stroke 2 or more years after the initial event. The remaining 111 patients had an ongoing risk of recurrent stroke (1.9 per 100 patient-years) despite long-term transfusions (P =.038).
CONCLUSIONS: The absence of an antecedent or concurrent medical event associated with an initial stroke is a major risk factor for subsequent stroke while receiving regular transfusions.

Entities:  

Mesh:

Year:  2002        PMID: 11953734     DOI: 10.1067/mpd.2002.122498

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  52 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

2.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Authors:  Russell E Ware; Ronald W Helms
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

3.  Plasma glial fibrillary acidic protein levels in a child with sickle cell disease and stroke.

Authors:  William J Savage; Allen D Everett; James F Casella
Journal:  Acta Haematol       Date:  2010-11-24       Impact factor: 2.195

4.  Sickle cell disease: primum non nocere (first do no harm).

Authors:  Mariane de Montalembert; Irene Roberts
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

5.  Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy.

Authors:  Erin M Hall; Jeffrey Leonard; Jodi L Smith; Kristin P Guilliams; Michael Binkley; Robert J Fallon; Monica L Hulbert
Journal:  Pediatr Blood Cancer       Date:  2016-04-22       Impact factor: 3.167

Review 6.  Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.

Authors:  Kristin P Guilliams; Melanie E Fields; Michael M Dowling
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

Review 7.  Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants.

Authors:  Shalini Shenoy
Journal:  Stem Cells Transl Med       Date:  2013-04-11       Impact factor: 6.940

8.  Pediatric and newborn stroke.

Authors:  Sharon Goodman; Steven Pavlakis
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

9.  Incomplete implementation of guideline-based stroke prevention therapy in sickle cell disease.

Authors:  Alyssa M Schlenz; Joannie Hayes; Martina Mueller; Shannon Phillips; Robert J Adams; Julie Kanter
Journal:  Am J Hematol       Date:  2018-08-06       Impact factor: 10.047

10.  National trends in incidence rates of hospitalization for stroke in children with sickle cell disease.

Authors:  Timothy L McCavit; Lei Xuan; Song Zhang; Glenn Flores; Charles T Quinn
Journal:  Pediatr Blood Cancer       Date:  2012-11-14       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.